TrioxNano Ltd. @2015 

Building 4.4.1 Edmond Safra Campus

Givaat Ram Jerusalem zip 91390

Tel 972-544597706 

Our nano machines are made from mesoporous 300 nm silica structures encapsulated by our unique caps. Each of our particles is loaded with one of 3 chemotherapies currently used according to combination TNBC guidelines (doxorubicin, Mitoxantrone and Docetaxel). According to preclinical studies conducted in animals our technology creates 10 folds higher concentration of the active chemotherapy in

the target cancer tissue.

Our Mission

Prof Itamar Willner chief chemical adviser

 Institute of Chemistry, Center for Nano Science and Nanotechnology,  The Hebrew University of Jerusalem.

 Innovations Award – 1998, 2004 Max Planck Research Award for International Cooperation – 1998 Israel Chemical Society Award – 2001 Israel Prize in Chemistry – 2002 Member of The Israel Academy of Sciences – 2002 The Klachky Family Prize for the Advancement of the Frontiers of Science – 2003 Member of the European Academy of Sciences and Arts - 2004 Honorary Guest Professorship, Tsinghua Univesity, Beijing, China – 2005 Honorary Professor, East China University of Science and Technology, Shanghai, China – 2007 Rothschild Prize in Chemistry – 2008 EMET Prize in Chemistry (under the auspices of the Prime Minister of Israel) – 2008 Fellow of the Royal Society of Chemistry (FRSC), UK – 2009 Member of the German National Academy of Sciences Leopoldina – 2009 ACS Nano Lectureship Award – 2013 Grand Professor –Technical University Dresden, CFAED program – 2014 and 2015 Thomson Reuters – Highly Cited Researcher and listed in the World’s Most Influential Scientific Minds – 2014 and 2015 Publications: Over 725 papers and 30 patents. h-index (Web of Science): 114 h-index (Google Scholar): 129


Axel Dassal, Phd

Regulatory manager

 

Our Technology





TXN613

PH / LACTATE 

sensitive

  • Why mesoporous silica
  • Our vision

  • Contact us

We strive to develop an efficient and 

comprehensive therapy to TNBC (Triple Negative Breast cancer) the most aggressive subtype of 

breast  cancer (med PFS 6-12 mos). It is considered an orphan indication. On October 2014 FDA recognizing the need for better treatment options and published guidelines allowing the use of the pCR endpoint setting to support approval of

treatments.

  

Patented (WO 2014087410) S.M.A.R.T (Stimuli Multi Adjusted Responsive Technology) nano machines have the ability to sense and react to their enviroment, by measuring the levels of at

least 2 preset variables(Mg/ATP/Ph/Lactate & other variable levels). Once preprogrammed threshold levels are encountered in the cancer cell enviroment our unique caps open and the particle unloads its chemotherapy 

payload.

Meet Our Team

Ofra Beni, Phd

​Chief Biolgy Adviser

 

Our technology is based on the work

of prof. Itamar willner's Group

Joseph Farfara, Msc

Chief Executive Officer.

TXN770

Mg / atp

sensitive

 Our Project in details





Roye Farfara, MD

Chief Technology Officer




Our Technology

Additional information about our project

Eti Sharon, Phd

Chief Lab Manager

Dov Melamed, Phd

​Chief Mfc Officer

 

TrioxNano 

Triox Nano is an Israeli innovative biotech

company developing novel solutions for human disease based on our patented S.M.A.R.T “Stimuli Responsive” nano machine technology.
Our mission is to develop a conclusive treatment (TXN018) to TNBC 
(Triple Negative Breast Cancer) based on the synergistic activity of 3 of our patented Nano machines:

TXN770(primary tumor), TXN613(Metastatis and Cancer stem Cell) TXN252(vascular bed) 

TrioxNano

S.M.A.R.T -  Stimuli Multi Adjusted Responsive (nano) Technology

TXN252*** / ***

sensitive